Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • RRD International

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    - PMLiVE

    Takeda’s mezagitamab shows promise in immune thrombocytopenia

    The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

    - PMLiVE

    Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

    Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

    - PMLiVE

    Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

    The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

    - PMLiVE

    Takeda shares late-stage results for investigational soticlestat in rare epileptic disorders

    Dravet syndrome and Lennox-Gastaut syndrome are drug-resistant to many anti-seizure medications

    - PMLiVE

    Takeda’s enzyme replacement therapy recommended by CHMP for rare blood clotting disorder cTTP

    If approved, rADAMTS13 will be the first and only enzyme replacement therapy in the EU indicated for cTTP

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links